These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10691291)

  • 21. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
    Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
    J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Purification and preliminary characterization of brain aspartoacylase.
    Moore RA; Le Coq J; Faehnle CR; Viola RE
    Arch Biochem Biophys; 2003 May; 413(1):1-8. PubMed ID: 12706335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
    Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
    Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
    Baslow MH
    J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
    Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
    J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathophysiology and Treatment of Canavan Disease.
    Pleasure D; Guo F; Chechneva O; Bannerman P; McDonough J; Burns T; Wang Y; Hull V
    Neurochem Res; 2020 Mar; 45(3):561-565. PubMed ID: 30535831
    [No Abstract]   [Full Text] [Related]  

  • 28. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination.
    Kirmani BF; Jacobowitz DM; Namboodiri MA
    Brain Res Dev Brain Res; 2003 Jan; 140(1):105-15. PubMed ID: 12524181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of aspartoacylase activity disrupts survival and differentiation of neural progenitors and oligodendrocytes in a mouse model of Canavan disease.
    Kumar S; Biancotti JC; Matalon R; de Vellis J
    J Neurosci Res; 2009 Nov; 87(15):3415-27. PubMed ID: 19739253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pathogenesis of, and pharmacological treatment for, Canavan disease.
    Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
    Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain damage results in down-regulation of N-acetylaspartate as a neuronal osmolyte.
    Baslow MH; Suckow RF; Gaynor K; Bhakoo KK; Marks N; Saito M; Saito M; Duff K; Matsuoka Y; Berg MJ
    Neuromolecular Med; 2003; 3(2):95-104. PubMed ID: 12728192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.
    Moffett JR; Ross B; Arun P; Madhavarao CN; Namboodiri AM
    Prog Neurobiol; 2007 Feb; 81(2):89-131. PubMed ID: 17275978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
    Becker I; Wang-Eckhardt L; Eckhardt M
    J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accumulation of N-acetyl-L-aspartate in the brain of the tremor rat, a mutant exhibiting absence-like seizure and spongiform degeneration in the central nervous system.
    Kitada K; Akimitsu T; Shigematsu Y; Kondo A; Maihara T; Yokoi N; Kuramoto T; Sasa M; Serikawa T
    J Neurochem; 2000 Jun; 74(6):2512-9. PubMed ID: 10820213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo.
    Francis JS; Strande L; Pu A; Leone P
    Glia; 2011 Oct; 59(10):1435-46. PubMed ID: 21608034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
    Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
    Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oligodendrocytes Do Not Export NAA-Derived Aspartate In Vitro.
    I Amaral A; Hadera MG; Kotter M; Sonnewald U
    Neurochem Res; 2017 Mar; 42(3):827-837. PubMed ID: 27394419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Murine aspartoacylase: cloning, expression and comparison with the human enzyme.
    Namboodiri MA; Corigliano-Murphy A; Jiang G; Rollag M; Provencio I
    Brain Res Mol Brain Res; 2000 May; 77(2):285-9. PubMed ID: 10837925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical clinical and radiological course of a patient with Canavan disease.
    Sarret C; Boespflug-Tanguy O; Rodriguez D
    Metab Brain Dis; 2016 Apr; 31(2):475-9. PubMed ID: 26586007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.